ILLUMINATE 301: ipilimumab versus IMO-2125 combined with ipilimumab in anti PD 1 refractory melanoma

Keynote lecture: Mutation signatures and targeting the DNA damage response

Dosing regiment in the combination of ipilimumab and nivolumab in stage III melanoma

COLUMBUS: Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma

Modern melanoma treatment in the UK

Latest advances in treatment for ALK positive NSCLC

The case for biosimilars

Highlights in early non-metastatic NSCLC and thoracic tumours

Anti–PD-L1 atezolizumab or chemotherapy as second-line therapy in patients with SCLC

Combination strategies of immunotherapy in breast cancer

Highlights in SCLC from ESMO 2018

Safety analysis of entrectinib for NTRK fusion tumours